April 28, 2022
Moderna has applied for emergency use authorization (EUA) for its COVID-19 vaccine for children under 6, company officials announced today.
The company plans to finish submitting the data for its full application for children between 6 months and 6 years old by May 9, The New York Times reported. The application joins the company’s previous requests for review of its vaccine for children between 6 and 11, and between 12 and 17.
"We are proud to share that we have initiated our EUA submission for authorization for our COVID-19 vaccine for young children," Moderna CEO Stéphane Bancel said in a statement. "We believe mRNA-1273 will be able to safely protect these children against SARS-CoV-2, which is so important in our continued fight against COVID-19 and will be especially welcomed by parents and caregivers."
Here’s what you need to know:
HAP will continue to monitor the latest COVID-19 public health developments and provide updates to members.
More information about Moderna’s application is available online.
Click on topic below for category-specific news articles.
Support a healthier Pennsylvania.